Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective
Applied Health Economics and Health Policy · 2024
DOI: 10.1007/s40258-024-00897-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, 2024. Verfasst von Maryia Zhdanava und 9 weiteren Autor:innen. Beteiligte Einrichtung: Analysis Group, Inc., Montréal, QC, Canada. Masha.Zhdanava@analysisgroup.com. Hauptthemen laut MEDLINE: Myasthenia Gravis, Health Care Costs, Machine Learning. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson Innovative Medicine, LLC.
Abstract (Originalsprache)
BACKGROUND: High healthcare costs could arise from unmet needs. This study used random forest (RF) and regression methods to identify predictors of high costs from a US payer perspective in patients newly diagnosed with generalized myasthenia gravis (gMG). METHODS: Adults with gMG (first diagnosis = index) were selected from the IQVIA PharMetrics® Plus database (2017-2021). Predictors of high healthcare costs were measured 12 months pre-index (main cohort) and during both the 12 months pre- and post-index (subgroup). Top 50 predictors of high costs [≥ $9404 (main cohort) and ≥ $9159 (subgroup) per-patient-per-month] were identified with RF models; the magnitude and direction of association were estimated with multivariable modified Poisson regression models. RESULTS: The main cohort and subgroup included 2739 and 1638 patients, respectively. In RF analysis, the most important predictors of high costs before/on the index date were index MG exacerbation, all-cause inpatient admission, and number of days with corticosteroids. After the index date, these were immunoglobulin and monoclonal antibody use and number of all-cause outpatient visits and MG-related encounters. Adjusting for the top 50 predictors, post-index immunoglobulin use increased the risk of high costs by 261%, monoclonal antibody use by 135%, index MG exacerbation by 78%, and pre-index all-cause inpatient admission by 27% (all p < 0.05). CONCLUSIONS: This analysis links patient characteristics both before the formal MG diagnosis and in the first year to high future healthcare costs. Findings may help inform payers on cost-saving strategies, and providers can potentially shift to targeted treatment approaches to reduce the clinical and economic burden of gMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Analysis Group, Inc., Montréal, QC, Canada. Masha.Zhdanava@analysisgroup.com.
- Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Titusville, NJ, USA.
- Analysis Group, Inc., Montréal, QC, Canada.
- Janssen Global Services, Titusville, NJ, USA.
- Department of Neurology and Neurosciences, Rutgers-New Jersey Medical School, Newark, NJ, USA.
ORCID-Profile: Maryia Zhdanava
Förderung
- Johnson & Johnson Innovative Medicine, LLC
Zitieren
APA
Zhdanava, M., Pesa, J., Boonmak, P., Schwartzbein, S., Cai, Q., Pilon, D., Choudhry, Z., Lafeuille, M. H., Lefebvre, P., & Souayah, N. (2024). Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-024-00897-x
Vancouver
Zhdanava M, Pesa J, Boonmak P, Schwartzbein S, Cai Q, Pilon D, et al. Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective. Applied Health Economics and Health Policy. 2024. doi:10.1007/s40258-024-00897-x
BibTeX
@article{Zhdanava2024,
author = {Zhdanava, Maryia and Pesa, Jacqueline and Boonmak, Porpong and Schwartzbein, Samuel and Cai, Qian and Pilon, Dominic and Choudhry, Zia and Lafeuille, Marie-Hélène and Lefebvre, Patrick and Souayah, Nizar},
title = {Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective},
journal = {Applied Health Economics and Health Policy},
year = {2024},
doi = {10.1007/s40258-024-00897-x}
}
EUVIMED